Mainstream

Exelixis outlines continued cabozantinib growth and zanzalintinib pipeline acceleration as new launches drive 19% revenue increase

Exelixis outlines continued cabozantinib growth and zanzalintinib pipeline acceleration as new launches drive 19% revenue increase

Post ContentexelRead More

You might also be interested in reading XRP ETFs absorb 80M tokens: Is a new bull trend starting for the altcoin?.

July 29, 2025
In Mainstream